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 Drug research and development facil-
itates the synthesis and release of novel 
therapeutics into clinical practice at a 
re markable rate. Th eir availability has 
undoubtedly revolutionized the treatment 
of numerous diseases — in particular, dev-
astating processes such as HIV infection. 
Th e landscape of this disease has been 
forever changed by the availability of 
highly active antiretroviral therapy 
(HAART) since 1996. Th e basic premise 
behind this strategy is to attack the virus 
at diff erent replication steps using multi-
ple medications. Unfortunately, most suc-
cess stories have a catch; in this case, the 
price of success is drug-induced kidney 
disease, a challenging complication for 
HIV   +   patients and their caregivers. 1 
 Before the widespread use of HAART, 
HIV-associated kidney disease was 
 primarily due to direct and / or indirect 
eff ects of the virus. However, with success-
ful treatment of HIV infection, drug-
induced nephrotoxicity ( Table 1 ) surfaced 
as an important problem. Acute kidney 
injury (AKI), various tubulopathies, 
 nephrolithiasis, and chronic kidney 
 disease were noted. 1 HAART causes these 
renal syndromes via multiple mecha-
nisms, including direct tubular toxicity, 
allergic reactions, and precipitation of 
insoluble drug crystals. 
 Although many of the early drugs had 
intolerable adverse eff ects and diffi  cult 
dosing schedules, newer agents have over-
come many of these issues. One such 
drug, tenofovir, has gained widespread 
use on the basis of its effi  cacy, tolerability, 
and patient-friendly dosing schedule. 2 As 
it is structurally similar to the acyclic 
nucleotide analogs adefovir and cidofovir, 
which are nephrotoxic, concern about 
adverse renal eff ects existed for tenofovir 
as well. Th ese two drugs cause proximal 
tubulopathies such as AKI as a result 
of acute tubular necrosis (ATN) and 
Fanconi ’ s syndrome, 3 by disrupting proxi-
mal tubular mitochondrial function. A 
number of mechanisms underlie drug-
induced mitochondriopathies, but these 
drugs act primarily by decreasing mito-
chondrial DNA (mtDNA) replication by 
inhibiting mitochondrial DNA poly-
merase-  , which is the only enzyme capa-
ble of replicating mtDNA. 3 As a result, 
mtDNA and a number of the mtDNA-
encoded enzymes involved in electron 
transport chain function and oxidative 
phosphorylation are depleted, resulting in 
disturbed mitochondrial function. Th is 
ultimately causes, among other eff ects, a 
defi cit in adenosine triphosphate produc-
tion, impaired cell function, and cell 
injury and / or death. 
 Early randomized clinical trials 4 and 
post-marketing data 5 examining tenofovir 
in relatively healthy HIV   +   subjects sup-
ported an excellent safety profi le, includ-
ing the absence of signifi cant renal injury. 
An  in vitro experimental study supported 
this clinical fi nding. 6 Th e investigators 
exposed various cultured human cell lines 
(liver, muscle, proximal renal tubule) to 
tenofovir. Minimal mtDNA depletion and 
insignifi cant reductions in cellular expres-
sion of the mitochondrial protein cyto-
chrome  c oxidase were noted with 
tenofovir. However, with the release of 
tenofovir into clinical practice and its use 
in HIV patients with various comorbid 
conditions, reports of nephrotoxicity 
began to surface. 7 Th ese reports described 
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renal consequences such as AKI from 
toxic ATN, Fanconi ’ s syndrome, and rare 
cases of nephrogenic diabetes insipidus. 
Renal histopathology from these cases 
demonstrated acute tubular injury pre-
dominantly in the proximal tubules, as 
described with adefovir and cidofovir. 
Th ese observations questioned the renal 
safety noted in the large clinical trials. 
 Further information about nephrotoxic 
potential was gleaned from a retrospective 
study that examined mitochondrial 
ultrastructure and mtDNA levels in kid-
ney tissue obtained from biopsies per-
formed for nephrotoxicity in HIV   −   and 
HIV   +   patients. 8 Investigators found that 
HIV   +   kidneys exposed to tenofovir had 
altered tubular mitochondrial morpho-
logy. However, while HIV   +   kidneys had 
mtDNA levels lower than those in HIV   −  
patients, there was no difference in 
mtDNA levels in tenofovir-exposed versus 
unexposed HIV   +   kidneys. Furthermore, 
HIV   +   / tenofovir   +   / didanosine   +   kidneys 
had lower mtDNA levels than HIV   +   -
 tenofovir   +   / didanosine   −   kidneys, which 
questioned whether mitochondrial 
 toxicity was a signifi cant complication of 
isolated tenofovir exposure. More recently, 
two animal studies support the notion 
that tenofovir causes mtDNA depletion 
and mitochondrial dysfunction. 9,10 A 
study in HIV   +   transgenic mice and their 
wild-type littermates examined ultrastruc-
ture and mtDNA levels with tenofovir, 
didanosine, and vehicle exposures. 9 Only 
renal proximal tubules from HIV   +   trans-
genic mice exposed to tenofovir showed 
ultrastructural mitochondrial abnormali-
ties (irregular shapes with sparse, frag-
mented cristae) and decreased mtDNA 
levels, which paralleled the ultrastructural 
mitochondrial abnormalities. Th e oppo-
site was seen in liver cells, where didano-
sine depleted hepatic mtDNA and 
tenofovir had no eff ect. Another study 
explored the potential for mitochondrial 
toxicity in rats exposed to tenofovir, dida-
nosine, or water. 10 Rats exposed to teno-
fovir, but not those exposed to didanosine 
or water, developed proximal tubular 
dilatation, abnormalities in mitochondrial 
ultrastructure, depleted mtDNA, and 
depressed respiratory chain enzyme 
expression (cytochrome  c oxidase and 
nicotinamide adenyldinucleotide dehy-
drogenase). In contrast, didanosine 
induced significant hepatic mtDNA 
depletion, whereas tenofovir had no liver 
eff ects. Th ese studies suggest that teno-
fovir causes compartmentalized mito-
chondrial toxicity within renal proximal 
tubular cells. 
 Herlitz and colleagues 11 (this issue) now 
make a strong case for tenofovir as a prox-
imal tubular mitochondrial toxin in 
humans. Th e Columbia University group 
queried their renal biopsy archives in 
search of a histopathologic correlate to the 
clinical renal disease — tenofovir-associ-
ated nephrotoxicity. According to prede-
fi ned diagnostic criteria, 13 patients with 
HIV infection were identifi ed. All patients 
were on various forms of HAART; and the 
ten with available data had well-controlled 
HIV infection by CD4 count and viral 
load. Duration of tenofovir ranged from 3 
weeks to 8 years with a median of 8 
months. Biopsy was performed for AKI 
( n  =  9) or proteinuria with mild serum 
creatinine elevation ( n  =  4). Mean serum 
creatinine at biopsy was 5.7 ± 4.0  mg / dl, 
mean proteinuria was 1.6 ± 0.3  g / d, and fi ve 
patients had normoglycemic glycosuria, 
the latter two fi ndings being suggestive of 
Fanconi ’ s syndrome. AKI was severe 
enough to require hemodialysis in fi ve 
patients. Of 11 cases with mean follow-up 
of nearly 20 months, kidney function 
returned to baseline in six cases, while fi ve 
had partial recovery. No patient remained 
on dialysis. Th us, although all patients had 
signifi cant recovery with tenofovir dis-
continuation, nearly half of the patients 
were left  with some level of CKD. 
 Renal histology demonstrated proxi-
mal tubular injury and varying degrees 
of chronic tubulointerstitial scarring. Ten 
cases had fi ndings consistent with  ‘ toxic 
ATN. ’ Prominent eosinophilic inclusions 
within proximal tubular cell cytoplasm, 
which represented giant, abnormal mito-
chondria, were noted on light micro-
scopy and constitute an interesting new 
fi nding. Th ese inclusions are easily iden-
tifi able, as they stain brightly with hema-
toxylin and eosin stain or fuchsinophilic 
with trichrome stain. On electron micros-
copy, mitochondria varied widely in 
shape and size; some were small and 
rounded, while others were swollen with 
irregular contours. Loss and disorienta-
tion of cristae were observed in enlarged 
mitochondria, while the overall number 
of mitochondria was significantly 
decreased in some tubular cells. 
 The comprehensive clinical – his-
topathologic correlation described in this 
paper addresses a number of issues related 
to tenofovir nephrotoxicity. First, it con-
fi rms that tenofovir causes  ‘ toxic ATN ’ of 
varied severity and Fanconi ’ s syndrome 
in exposed HIV   +   patients. Second, 
patients can develop the clinical renal 
syndrome at any time point in tenofovir 
therapy, both early and late. Third, 
although tenofovir discontinuation is 
associated with signifi cant renal recovery, 
many patients may suffer from CKD. 
Finally, histopathology confirms that 
tenofovir is a mitochondrial toxin in renal 
tubular cells and has a distinctive fi nding 
on light microscopy. However, the study 
does not answer one important question: 
Why does tenofovir cause renal injury in 
only a small subset of HIV   +   patients? To 
try to answer this question, host charac-
teristics and drug pharmacokinetics must 
be considered. 
 Table 1  |  HAART-associated kidney 
disease 
 Renal syndrome  Medication 
 Acute kidney injury 
  Toxic acute 
tubular necrosis 
 Tenofovir, ritonavir, 
didanosine 
  Acute interstitial 
nephritis 
 Atazanavir, abacavir, 
indinavir 
  Crystal 
nephropathy 
 Indinavir, atazanavir 
 Tubulopathies 
  Fanconi’s 
syndrome 
 Tenofovir, didanos-
ine, ritonavir 
  Renal tubular 
acidosis 
 Lamivudine, stavu-
dine 
  Nephrogenic 
diabetes insipidus 
 Tenofovir, didanos-
ine, indinavir 
 Nephrolithiasis  Indinavir, atazanavir, 
nelfi navir, ampre-
navir, saquinavir, 
efavirenz 
 Chronic kidney disease 
  Chronic intersti-
tial nephritis 
 Indinavir, tenofovir 
  Post-AKI kidney 
disease 
 Several HAART 
drugs 
 Abbreviations: AKI, acute kidney injury; HAART, highly 
active antiretroviral therapy. 
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 Host factors that potentially enhance 
tenofovir nephrotoxicity include mtDNA 
depletion, a complication of HIV infec-
tion itself, which likely primes patients for 
more severe mitochondrial dysfunction 
with exposure to a drug that targets this 
organelle. In addition, underlying kidney 
disease with low glomerular fi ltration rate 
and genetic defects in certain renal drug 
excretion pathways also enhance risk for 
tenofovir-induced nephrotoxicity. 12 Teno-
fovir is eliminated by a combination of 
glomerular fi ltration and proximal tubular 
secretion, which in part explains the 
 compartmental toxicity of tenofovir. 12 
Tenofovir is transported via organic anion 
transporter-1 (OAT-1) from the baso-
lateral circulation into proximal tubular 
cells ( Figure 1 ), where it is eventually 
 translocated into the urine through apical 
efflux transporters such as multidrug 
resistance protein-2 (MRP-2) and MRP-4. 
Renal impairment with reduced glomeru-
lar fi ltration rate will increase the amount 
of tenofovir that is secreted, increasing 
traffi  cking through the proximal tubular 
cells. Increased activity of OAT-1 may 
increase the amount of tenofovir enter-
ing proximal tubular cells, although this 
remains unproven. Impaired MRP-
driven effl  ux activity can reduce tenofo-
vir secretion and increase intracellular 
concentrations. A single-nucleotide 
polymorphism in the MRP-2 effl  ux trans-
porter gene ( ABCC2 ) has been docu-
mented in HIV   +   patients who developed 
tenofovir-induced nephrotoxicity, sup-
porting this hypothesis. 13 Similarly, 
endogenous anions and other drugs 
may compete with tenofovir for these 
effl  ux transport pathways. 
 Ultimately, these excretory pathway 
defects can lead to increased tenofovir 
traffi  cking through and / or increased con-
centrations within proximal tubular cells, 
enhancing risk for mtDNA depletion and 
mitochondrial dysfunction. In a subgroup 
of patients, these energy-defi cient tubular 
cells may manifest as the clinical renal 
syndromes previously described. The 
actual development and onset time of 
tenofovir-induced nephrotoxicity will 
likely depend on the number and severity 
of patient risk factors present. Genetic 
risk factor testing (for the single-nucle-
otide polymorphism in  ABCC2 ) to iden-
tify high-risk patients and targeted 
interventions, such as probenecid to 
reduce OAT-1 transport of tenofovir into 
tubular cells, may allow HIV   +   patients to 
garner benefi t from eff ective therapies 
such as tenofovir. 
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 Figure 1  |  Proximal tubular cell transport pathway for tenofovir. ( a ) The organic anion drug 
tenofovir (TF) is delivered to the basolateral membrane of proximal tubular cells and is transported 
into the cell by organic anion transporter-1 (OAT-1). Once within the cell, TF is transported 
via carrier proteins and is subsequently secreted into the urinary space by the apical efflux 
transporters multidrug resistance protein-2 (MRP-2) and MRP-4. ( b ) Disturbances in the secretory 
pathway of TF (increased OAT-1 activity or decreased MRP efflux transport activity) may lead to 
increased TF concentrations within the cell, which can cause mitochondrial DNA depletion and 
dysfunction. This can ultimately cause a proximal tubulopathy characterized by acute kidney injury 
and Fanconi ’ s syndrome. Abbreviations: NaDC, sodium – dicarboxylate symporter; OCT, organic 
cation transporter; Pgp, P-glycoprotein. 
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 Probiotics and dietary 
manipulations in calcium 
oxalate nephrolithiasis: two 
sides of the same coin? 
 Loris  Borghi 1 ,  Antonio  Nouvenne 1 and  Tiziana  Meschi 1  
 Growing evidence has assigned to oxalate a pivotal role in calcium 
nephrolithiasis pathophysiology. A better understanding of the 
mechanisms behind intestinal absorption and renal excretion has led to 
the identification of new treatments. Among these, diet and probiotics 
appear promising in terms of safety and rationale. However, the 
discrepancy between  in vitro and  in vivo results requires further studies 
to identify the right patient target, the correct dosage, and the real 
modification of natural and clinical history of nephrolithiasis. 
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 In recent decades, an advance in technol-
ogy has led to an improvement in the 
 effi  cacy of urological treatments for idio-
pathic calcium nephrolithiasis. From 
a pathophysiological point of view, 
in-depth studies — for example, those car-
ried out on Randall ’ s plaques and molecu-
lar aspects — have allowed better defi nition 
of the illness and currently weaken the 
hypothesis that nephrolithiasis is a simple 
combination of chemical – physical factors 
that induce crystallization. 1 Nevertheless, 
the prevalence of calcium oxalate nephro-
lithiasis is rising in industrialized coun-
tries, and we can still consider this disease 
an  ‘ orphan ’ of eff ective drugs. 
 This becomes crucial because the 
apparent role of oxalate in determining 
the risk and development of calcium 
nephrolithiasis seems to be increasing; 
according to some, it is more relevant 
than calcium itself. This is true both for 
 simple chemical – physical and stoichiomet-
ric events in the crystallization process, 
which cause small variations in the 
 concentrations of urinary oxalate to 
determine greater changes in calcium 
oxalate supersaturation values, and for 
our growing knowledge of other mecha-
nisms involved. For example, the renal 
reabsorption of oxalate is linked to other 
ions (sulfate, chloride, other anions) 
through a specifi c family of transporters, 
solute carrier family 26A (SLC26A); 2 in 
fact, patients with cystic fi brosis in which 
there is a defect in the chloride channel 
CFTR, which is co- regulated with some 
receptors of the SLC2A family, show 
hyperoxaluria and an increased  incidence 
of calcium oxalate nephrolithiasis. More-
over, oxalate itself seems to reduce renal 
blood fl ow and is responsible for micro-
vascular damage due to an insufficient 
crystal clearance; it has been suggested that 
this is one of the  possible mechanisms 
explaining the greater prevalence of neph-
rolithiasis in hypertensive subjects. In fact, 
it has been demonstrated that the admin-
istration of  ‘ vasodilators ’ such as enalapril 
or losartan in rats with ethylene glycol-
induced nephrolithiasis reduces tubu-
lointerstitial lesions. Finally, interactions of 
oxalate with renal epithelium could induce 
oxidative stress with apoptotic and regen-
erative stimu lus and greater crystal adhe-
sion capacity. 
 It is therefore clear how important and 
at the same time how complex the medical 
treatment of idiopathic calcium nephro-
lithiasis is. An interesting study by Lieske 
 et al. 3 (this issue) shows the diffi  culty of 
translating research on calcium oxalate 
nephrolithiasis from bench to bedside; 
assumptions based on excellent  in vitro 
studies have proved to be ineffi  cient in 
 in vivo experiments. 
 Must we, therefore, conclude that pro-
biotics are ineff ective in the treatment of 
calcium nephrolithiasis? Probably not. 
Th e problem is rather to identify in which 
patients they actually work. In fact, given 
the variable absorption of oxalate in the 
gastrointestinal tract (from 7 % to 72 % ), 
the amount of oxalate intake in the diet 
becomes crucial. It is not surprising that 
major proof of a fall in oxaluria following 
the use of probiotics derives from studies 
that analyzed patients with enteric hyper-
oxaluria 4 or aft er an oral load of oxalate; 5 
in contrast, results with mild hyperoxalu-
ria are not very satisfactory. 6 
 Many factors are involved in determin-
ing the amount of gastrointestinal oxalate 
absorption. We can identify at least four 
pivotal points: 1,2,7 (1) the amount of solu-
ble oxalate and / or its precursors that is 
naturally present in foods; (2) other foods 
or nutrients that can infl uence the absorp-
tion of oxalate because of competition or 
formation of non-absorbable complexes 
(for example, calcium, magnesium, lipids, 
fi ber); (3) intestinal fl ora and the pres-
ence of microorganisms capable of 
metabolizing oxalate; and (4) variations 
of pH and density of anion transporters 
